What does "therapeutics company" mean?

A company that develops drugs to treat or prevent disease, as distinct from contract manufacturers (CDMOs), service organizations (CROs), or tools/diagnostics suppliers. Therapeutic developers own a pipeline of drug candidates and either develop them in-house, license them out, or commercialize them at scale.

Which European countries lead in therapeutics?

Switzerland (Roche, Novartis, Idorsia, Basilea, Noema), Germany (BioNTech, Bayer, Merck KGaA), Denmark (Novo Nordisk, Lundbeck, Genmab, Zealand Pharma), Sweden (AstraZeneca, BioArctic, Sobi), and emerging markets in Poland (Ryvu, Captor), Lithuania (Atrandi, CasZyme), and Estonia (Asper Biogene). The directory covers all of these with hand-reviewed profiles.

How are therapeutics companies verified in this directory?

Every profile is hand-reviewed against an audit framework: leadership identity confirmed by primary source, physical site address sourced from official disclosures, regulatory and pipeline context backed by certification documents or filings, and a registry note explaining the company's current operating focus and clinical stage where applicable.

Can I compare two therapeutic developers side by side?

Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.

13 therapeutics companies in Denmark

Copenhagen clinical-stage antibody-drug conjugate biotech with a first- and best-in-class pipeline led by ADCE-D01, a uPARAP-targeted ADC with FDA Fast Track designation for soft-tissue sarcoma.

Lead: Michael PehlChief Executive Officer
Scale: Clinical-stage ADC development

Nasdaq-listed clinical-stage biotech (GLTO) with Copenhagen operating headquarters, developing small-molecule galectin-3 and LOXL2 inhibitors for fibrosis, oncology, and inflammation.

Lead: Hans SchambyeChief Executive Officer
Scale: Clinical-stage small-molecule development

Copenhagen clinical-stage neuroscience biotech developing non-opioid chronic neuropathic pain and sensorineural hearing loss therapeutics, with lead candidate HB-086 targeting the peripheral nervous system.

Lead: Torsten M. MadsenChief Executive Officer
Scale: Early clinical-stage biotech

Aarhus clinical-stage neuromuscular biotech developing ClC-1 chloride-channel inhibitors to restore muscle function, with lead candidate NMD670 in Phase 2 for myasthenia gravis.

Lead: Thomas Holm PedersenCo-Founder and Chief Executive Officer
Scale: Clinical-stage small-molecule development

Aarhus preclinical immuno-oncology biotech developing STING-pathway priming small molecules to convert cold tumors into immune-responsive ones, with a 20 million EUR Series A financing completed in 2019.

Lead: Claus Elsborg OlesenCo-Founder and Chief Executive Officer
Scale: Preclinical small-molecule development

Frederiksberg vaccine company developing maternal immunization against Group B Streptococcus from a Copenhagen-area clinical-development base.

Lead: Per FischerCEO
Scale: Clinical-stage vaccine platform

Copenhagen biotech company developing novel therapies for atrial fibrillation and other cardiac arrhythmias from a Danish clinical-development base.

Lead: Anders Haahr MathiesenChief Executive Officer
Scale: Clinical-stage therapeutics platform

Copenhagen immuno-oncology company developing immune-modulating cancer therapeutics and clinical-stage vaccine-based programs from Denmark.

Lead: Mai-Britt ZoccaCEO
Scale: Clinical-stage therapeutics platform

Hellerup headquarters for TransCon-based endocrinology and rare-disease programs with public-company governance and expanding commercial operations.

Lead: Jan MikkelsenPresident and Chief Executive Officer
Scale: Global biopharma development and commercialization

Ballerup dermatology headquarters coordinating global specialty-pharma operations, regulatory governance, and medical dermatology portfolio execution.

Lead: Christophe BourdonChief Executive Officer
Scale: Global specialty-pharma operations

Copenhagen-area peptide therapeutics company focused on obesity, metabolic disease, and specialty indications through discovery and late-stage development.

Lead: Adam SteensbergPresident and Chief Executive Officer
Scale: Global Biopharma

Copenhagen antibody-therapeutics headquarters running Genmab's platform-engineering, translational science, and late-stage oncology execution from its Valby base.

Lead: Jan van de WinkelPresident and Chief Executive Officer
Scale: Global Biopharma

Copenhagen-area neuroscience therapeutics company combining brain-disease R&D, regulated pharmaceutical supply, and global commercial operations.

Lead: Charl van ZylPresident and CEO
Scale: Global Supply

Therapeutics companies in Denmark

Where does therapeutics cluster in Denmark?

Which standards are already visible?

Therapeutics profiles in Denmark

Adcendo ApS

Galecto, Inc.

Hoba Therapeutics ApS

NMD Pharma A/S

STipe Therapeutics ApS

MinervaX

Acesion Pharma

IO Biotech

Ascendis Pharma

LEO Pharma

Zealand Pharma

Genmab A/S

H. Lundbeck A/S

Read deeper on this category

EU Biotech Regulation 2026: What Changed and Who It Affects

Frequently asked questions on this category

Compare companies or open the wider market.